NovaBay Pharmaceuticals, Inc. CEO Comments On President Obama's 'Superbug' Budget Initiative And Reports By The Centers for Disease Control and Prevention (CDC) On Antibiotic Resistance

Published: Mar 07, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

EMERYVILLE, Calif., March 6, 2014 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE MKT:NBY), a clinical-stage biopharmaceutical company developing topical non-antibiotic anti-microbial products, today commented on President Obama's antibiotic resistance budget initiative, which includes $30 million annually for the next five years to detect and prevent "superbug" infections. Superbugs are of great concern because they are resistant to even the strongest antibiotics. Dr. Ron Najafi, Chairman and Chief Executive Officer of NovaBay commented on the worrisome new cases of antibiotic-resistant bacteria and on a plan that NovaBay scientists have developed to successfully fight the superbug threat.

Help employers find you! Check out all the jobs and post your resume.

Back to news